,59 In the atopic dermatitis anti-IgE pediatric double-blind, placebo-controlled randomized clinical trial (ADAPT), children with atopic dermatitis with median total IgE levels 8373 IU/mL (4556–18506 IU/mL) were treated with omalizumab or placebo for 24 weeks. Here, IGHE is linked to atopic eczema.